Cidara Therapeutics, Inc. officers and board members have only been selling lately: one insider reduced their stakes by about $2.2 million of stock over 12 months, with no open-market purchases.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | Ward Shane | COO | Sell | 9,959 | $220.08 | $2.2M | SEC |
| Sep 15, 2025 | Davarpanah Nicole Negar | Executive Officer | Sell | 474 | $62.86 | $30K | SEC |
| Jun 30, 2025 | Kolchinsky Peter | Director | Buy | 2,272,727 | $44.00 | $100.0M | SEC |
| Jun 4, 2025 | Mineo Chrysa | Director | Buy | 2,270 | $21.71 | $49K | SEC |
| Jun 4, 2025 | Mineo Chrysa | Director | Buy | 1,050 | $23.44 | $25K | SEC |
| Mar 13, 2025 | Ward Shane | COO | Sell | 1,664 | $21.96 | $37K | SEC |
| Mar 13, 2025 | Tari Leslie | Executive Officer | Sell | 1,773 | $21.96 | $39K | SEC |
| Sep 13, 2024 | Sandison Taylor | Executive Officer | Sell | 924 | $11.64 | $11K | SEC |
| Sep 13, 2024 | Tari Leslie | Executive Officer | Sell | 909 | $11.64 | $11K | SEC |
| Jun 11, 2024 | Stein Jeffrey | CEO | Buy | 8,000 | $13.21 | $106K | SEC |
| Mar 12, 2024 | Tari Leslie | Executive Officer | Sell | 21,029 | $0.67 | $14K | SEC |
| Mar 12, 2024 | Sandison Taylor | Executive Officer | Sell | 20,662 | $0.67 | $14K | SEC |
| Mar 12, 2024 | Ward Shane | COO | Sell | 20,473 | $0.67 | $14K | SEC |
| Mar 12, 2024 | Shah Preetam | CFO | Sell | 18,931 | $0.67 | $13K | SEC |
| Sep 13, 2023 | Tari Leslie | Executive Officer | Sell | 18,469 | $0.95 | $18K | SEC |
In the last 12 months Cidara Therapeutics, Inc. insiders made open-market purchases worth about $0 and sales worth about $2.2 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in CDTX was filed on 2025-12-12.
No congressional trades in CDTX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).